HomeCompareINKA vs JNJ

INKA vs JNJ: Dividend Comparison 2026

INKA yields 19.19% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INKA wins by $49.4K in total portfolio value
10 years
INKA
INKA
● Live price
19.19%
Share price
$10.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.5K
Annual income
$6,173.19
Full INKA calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — INKA vs JNJ

📍 INKA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINKAJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INKA + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INKA pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INKA
Annual income on $10K today (after 15% tax)
$1,630.93/yr
After 10yr DRIP, annual income (after tax)
$5,247.21/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, INKA beats the other by $4,543.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INKA + JNJ for your $10,000?

INKA: 50%JNJ: 50%
100% JNJ50/50100% INKA
Portfolio after 10yr
$44.7K
Annual income
$3,500.48/yr
Blended yield
7.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

INKA
No analyst data
Altman Z
-3.2
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INKA buys
0
JNJ buys
0
No recent congressional trades found for INKA or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINKAJNJ
Forward yield19.19%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$69.5K$20.0K
Annual income after 10y$6,173.19$827.78
Total dividends collected$38.6K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: INKA vs JNJ ($10,000, DRIP)

YearINKA PortfolioINKA Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,619$1,918.74$10,676$355.77+$1.9KINKA
2$15,765$2,262.81$11,407$389.39+$4.4KINKA
3$19,510$2,642.04$12,198$426.53+$7.3KINKA
4$23,932$3,055.85$13,056$467.62+$10.9KINKA
5$29,110$3,503.17$13,987$513.12+$15.1KINKA
6$35,131$3,982.41$14,998$563.56+$20.1KINKA
7$42,081$4,491.58$16,098$619.52+$26.0KINKA
8$50,055$5,028.28$17,295$681.69+$32.8KINKA
9$59,149$5,589.80$18,599$750.82+$40.5KINKA
10$69,463$6,173.19$20,022$827.78+$49.4KINKA

INKA vs JNJ: Complete Analysis 2026

INKAStock

KludeIn I Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on completing a business combination with a software or technology-enabled business serving consumers or enterprises in the United States. The company was incorporated in 2020 and is based in Berkeley, California.

Full INKA Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this INKA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INKA vs SCHDINKA vs JEPIINKA vs OINKA vs KOINKA vs MAININKA vs ABBVINKA vs MRKINKA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.